Publications by authors named "Stephen Mok"

Claim this Profile
A
Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1.
Stephen Mok, Huey Liu, Didem Ağaç Çobanoğlu, Nana-Ama A S Anang, James J Mancuso

Proc Natl Acad Sci U S A· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy.
Stephen Mok, Didem Ağaç Çobanoğlu, Huey Liu, James J Mancuso, James P Allison

Proc Natl Acad Sci U S A· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Deborah A Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok

J Clin Invest· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.
Lidia Robert, Christina Harview, Ryan Emerson, Xiaoyan Wang, Stephen Mok

Oncoimmunology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
Blanca Homet Moreno, Stephen Mok, Begonya Comin-Anduix, Siwen Hu-Lieskovan, Antoni Ribas

Oncoimmunology· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.
Richard Tavaré, Helena Escuin-Ordinas, Stephen Mok, Melissa N McCracken, Kirstin A Zettlitz

Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Deborah A Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok

J Clin Invest· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
Stephen Mok, Jennifer Tsoi, Richard C Koya, Siwen Hu-Lieskovan, Brian L West

BMC Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Siwen Hu-Lieskovan, Stephen Mok, Blanca Homet Moreno, Jennifer Tsoi, Lidia Robert

Sci Transl Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Lidia Robert, Jennifer Tsoi, Xiaoyan Wang, Ryan Emerson, Blanca Homet, Stephen Mok

Clin Cancer Res· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.
Stephen Mok, Richard C Koya, Christopher Tsui, Jingying Xu, Lídia Robert

Cancer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
Jingying Xu, Jemima Escamilla, Stephen Mok, John David, Saul Priceman

Cancer Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Deborah A Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok

J Clin Invest· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
Richard C Koya, Stephen Mok, Nicholas Otte, Kevin J Blacketor, Begonya Comin-Anduix

Cancer Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.
Erika von Euw, Mohammad Atefi, Narsis Attar, Connie Chu, Sybil Zachariah, Stephen Mok

Mol Cancer· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Fei Su, Amaya Viros, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Stephen Mok

N Engl J Med· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Rong Rong Huang, Jason Jalil, James S Economou, Bartosz Chmielowski, Richard C Koya, Stephen Mok

Clin Cancer Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.
Richard C Koya, Stephen Mok, Begoña Comin-Anduix, Thinle Chodon, Caius G Radu

Proc Natl Acad Sci U S A· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Jonas N Søndergaard, Ramin Nazarian, Qi Wang, Deliang Guo, Teli Hsueh, Stephen Mok

J Transl Med· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.
Dan D Vo, Robert M Prins, Jonathan L Begley, Timothy R Donahue, Lilah F Morris, Stephen Mok

Cancer Res· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosensitization with a Bcl-2 small molecule inhibitor.
Jonathan Begley, Dan D Vo, Lilah F Morris, Kevin W Bruhn, Robert M Prins, Stephen Mok

Cancer Immunol Immunother· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis